
    
      This is an open-label, non-comparative, non-interventional, prospective, and multi-center
      study conducted in Korean health care centers by accredited physicians (ie, investigators).
      The study population will be adult patients with moderately to severely active UC who have
      had an inadequate response or intolerance to the basic treatments or biological agents.
      Clinical Severity of Ulcerative Colitis is classified as mild, moderate, or severe based on
      the Mayo score or partial Mayo score. Xeljanz will be administered according to the "Dosage
      and Administration" of the approved labeling. There is no visit or activity mandated by this
      study. The investigator will collect patient data and record the information on each
      patient's case report form (CRF).
    
  